65,437 trials
Allergic Rhinitis
Primary: Change From Baseline Response in Albumin Levels in Nasal Lavage Following Each Challenge — -33.61; -82.2; -185.85; -41.87 ng/mL — p=>0.05
Myelodysplastic Syndromes
Primary: Percentage of Participants Who Achieved Hematologic Improvement in Erythroid Response (HI-E) Per International Working Group (IWG) Through Week 24 — 47.6 Percentage of…
Squamous Cell Carcinoma of Head and Neck
Primary: Overall Response Rate (ORR) Based on RECIST v1.1 — 0; 16.7 percentage of participants
COVID-19
Primary: Time to Sustained Clinical Improvement of at Least 2 Points — 7.0; 7.0 days
Chikungunya
Primary: Percentage of Participants With 4-fold Rise in Anti-CHIKV Neutralizing Antibody Response — 100; 100 percentage of participants — p=1
Human Immunodeficiency Virus
Primary: Number of Participants With Mucosal Binding IgG Antibodies to HIV CN54gp140 Antigen — 0; 3; 1; 6 Participants
Diffuse Large B-cell Lymphoma
Primary: Incidence and Severity of Treatment-emergent Adverse Events (TEAEs) — 33; 33; 31; 32 Participants
Childhood Obesity · Parenting · Mobile Phone Use
Primary: Child Weight — 45.6; 44.9 lbs
Chronic Low Back Pain
Primary: Low Back Pain - Numeric Pain Rating (NRS) Scale — 4.5; 4.3; 3.8; 3.4 units on a scale
Classical Hodgkin Lymphoma
Primary: Complete Response (CR) Rate at the End of Study Intervention as Assessed by Blinded Independent Central Review (BICR) Per Lugano 2014 Response Criteria — 67.0 Percentage…
Bariatric Surgery Candidate
Primary: Number and Types of Additional Tools Required to Mobilize the Liver During Procedure — 0 Additional Tools to Mobilize Liver
Labor Onset and Length Abnormalities · Pregnancy Related
Primary: Labor Agentry Scale — 57; 54 score on a scale
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Overall Response Rate (ORR) — 0.89 proportion of participants
HIV Infections
Primary: Number of Participants With Sustained Virologic Suppression at Year 3 — 119; 2; 1; 1 Participants
Healthy Volunteers · Adult · Pharmacokinetics
Primary: Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Ritlecitinib — 389.1; 398.3; 378.0; 387.8 nanogram*hour per…